Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-01-23 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the launch of a new therapeutic product, Extavia, for multiple sclerosis. It contains no financial statements, no detailed financial analysis, nor any regulatory certifications or voting results. It is a regulatory announcement providing material information to investors but does not constitute a full financial report or earnings release. Given the nature of the document as a Form 6-K filing with a press release, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2009-01-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the approval of four new medicines in Japan. It includes detailed information about the drugs, clinical trials, and market impact, but does not contain financial statements or detailed financial analysis. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial filing. It is a regulatory announcement of business developments and approvals. Given the nature of the Form 6-K and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2009-01-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing clinical study results for Sandostatin LAR, including detailed study data and safety information. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a transcript, audit report, or management change announcement. It is a regulatory filing used to disclose material information to investors outside of the annual or quarterly report cycle. Given the nature of the Form 6-K and the content being a press release with clinical study results, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (over 13,000 characters), indicating it is not a mere announcement of a report but a full disclosure document. Confidence in this classification is high due to the clear identification as a Form 6-K and the content type.
2009-01-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing a contract award from the US Department of Health and Human Services for building a vaccine manufacturing facility. It contains no financial statements or detailed financial analysis but is a regulatory announcement of a material event. The document is over 12,000 characters, so it is not a brief announcement of report availability. It is not an earnings release, annual report, or interim report. It is a regulatory filing reporting a significant contract and business update. Therefore, the best classification is Regulatory Filings (RNS).
2009-01-16 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. It contains an investor relations release about clinical trial results for Afinitor in advanced gastric cancer, including study details, safety profile, and future plans for Phase III trials. The document is informational and regulatory in nature, providing updates on clinical development and company activities but does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or quarterly report, earnings release, or management discussion. The document is a regulatory filing providing material information to investors and the SEC but does not fit into more specific categories like earnings release or management reports. Therefore, it best fits the category of Regulatory Filings (RNS). The document length is over 12,000 characters, indicating it is a substantive filing rather than a brief announcement or certification. Confidence in this classification is high given the clear identification as a Form 6-K and the content type.
2009-01-16 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.